DaVita (NYSE:DVA) Sets New 12-Month High – Should You Buy?

DaVita Inc. (NYSE:DVA) shares reached a new 52-week high on Friday . The company traded as high as $157.49 and last traded at $157.1610, with a volume of 337492 shares traded. The stock had previously closed at $152.54.

Wall Street Analyst Weigh In

Several analysts have weighed in on DVA shares. UBS Group upped their target price on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Truist Financial set a $158.00 price objective on shares of DaVita in a research note on Thursday, February 5th. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. TD Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $155.80.

DaVita Price Performance

The stock has a market cap of $10.49 billion, a price-to-earnings ratio of 15.84, a price-to-earnings-growth ratio of 0.52 and a beta of 0.99. The firm’s 50-day moving average is $123.36 and its 200 day moving average is $125.82.

DaVita (NYSE:DVA) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. The business had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, sell-side analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

Institutional Trading of DaVita

Institutional investors and hedge funds have recently bought and sold shares of the business. Elevation Wealth Partners LLC raised its holdings in DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after buying an additional 165 shares during the period. Hantz Financial Services Inc. lifted its holdings in shares of DaVita by 48.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. Caitlin John LLC acquired a new stake in DaVita in the 4th quarter valued at $34,000. Canada Pension Plan Investment Board purchased a new position in DaVita in the second quarter valued at about $43,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of DaVita in the fourth quarter worth about $45,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.